Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Lupeng Pharma Closes 2nd $35 Million Pre-B Tranche for Small Molecule Drugs

publication date: Nov 14, 2022

Guangzhou Lupeng Pharmaceutical completed its second $35 million pre-B tranche led by Kaitai Capital and Temasek. Temasek also led the previous $35 million pre-B tranche, which was completed one year ago. Founded in 2018, Lupeng aims to develop global best-in-class small molecule therapies for cancer, hepatitis B and autoimmune diseases. Currently, the company is conducting nine clinical trials of four clinical stage assets in China and the US. Its lead drug is a selective Bcl-2 inhibitor aimed at advanced leukemia while a second drug, a dual Bcl-2/Bcl-xl inhibitor, also targets cancer. More details....

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital